Evidence map›Paper›PMID 18378720›Full record

ArticleAntimicrobial agents and chemotherapy2008

Comparison of the essential cellular functions of the two murA genes of Bacillus anthracis.

G C Kedar, Vickie Brown-Driver, Daniel R Reyes, Mark T Hilgers, Mark A Stidham, Karen Joy Shaw, John Finn, Robert J Haselbeck

Abstract readComparative Study
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Fosfomycin: Mechanism and Resistance.Cold Spring Harbor perspectives in medicine · 2017
    Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

G C KedarTrius Therapeutics, Inc., 6310 Nancy Ridge Drive, Suite 105, San Diego, CA 92121, USA. kgc@triusrx.com
Vickie Brown-Driver
Daniel R Reyes
Mark T Hilgers
Mark A Stidham
Karen Joy Shaw
John Finn
Robert J Haselbeck

Funding

Novel Bacterial Cell Wall Biosynthesis Inhibitors for Biodefense TherapeuticsR43AI069666 · NIAID · TRIUS THERAPEUTICS, INC. · PI STIDHAM, MARK ALAN · 2006 to 2007
$1.2M
NIAID NIH HHS 1 R43 AI069666-01NIAID NIH HHS R43 AI069666
6 · The paper itself

Abstract

Targeted antisense and gene replacement mutagenesis experiments demonstrate that only the murA1 gene and not the murA2 gene is required for the normal cellular growth of Bacillus anthracis. Antisense-based modulation of murA1 gene expression hypersensitizes cells to the MurA-specific antibiotic fosfomycin despite the normally high resistance of B. anthracis to this drug.

Indexed as

Alkyl and Aryl TransferasesAnti-Bacterial AgentsBacillus anthracisBacterial ProteinsDrug Resistance, BacterialFosfomycinInhibitory Concentration 50Microbial Sensitivity TestsRNA, AntisenseAlkyl and Aryl TransferasesAnti-Bacterial AgentsBacterial ProteinsFosfomycinRNA, AntisenseUDP-N-acetylglucosamine 1-carboxyvinyltransferase

Identifiers

PMID18378720
PMCPMC2415750

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.